Home > Insider Trading > Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals Inc (KERX)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
41 - 49

Pitney Bowes Inc. (PBI), Cirrus Logic, Inc. (CRUS), Keryx Biopharmaceuticals (KERX): Here's What This $3 Billion Market Wizard Has Been Buying

Today, let's look at Tudor Investment, founded in 1980 by Paul Tudor Jones and featuring the flagship Tudor BVI fund.

Keep Reading →

April 1st, 2013 - News

Amarin Corporation plc (ADR) (AMRN), Exelixis, Inc. (EXEL): Here's What This 220% Gainer Has Been Buying and Selling

Today, let's look at Passport Capital, which was founded by John Burbank in 2000 and known for combining macroeconomic analysis and fundamental research.

Keep Reading →

March 20th, 2013 - Hedge Funds

3 Biotechs Still Burning Through Cash: Ariad Pharmaceuticals, Inc. (ARIA), Dynavax Technologies Corporation (DVAX), MannKind Corporation (MNKD)

Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue.

Keep Reading →

March 5th, 2013 - News

Is Now The Time To Buy Keryx Biopharmaceuticals (KERX)?

Recently, Keryx Biopharmaceuticals (NASDAQ:KERX) achieved a new milestone as the company declared remarkable results from its Phase 3 trials of Zerenex.

Keep Reading →

February 25th, 2013 - News

Peregrine Pharmaceuticals (PPHM)'s Epic Failure (Maybe)

Clinical trial 101 says if a trial passes all of its primary endpoints it's successful. If it doesn't, it's not.

Keep Reading →

February 14th, 2013 - News

Xerenex Kidney Treatment: A Game Changer for Keryx Biopharmaceuticals (KERX)

Keryx Biopharmaceuticals (NASDAQ:KERX)’s latest kidney drug called Zerenex is a game changer for the company after achieving positive results from its long-term Phase 3 study, which is the second and...

Keep Reading →

February 11th, 2013 - News

3 Horrendous Health-Care Stocks This Week: Accuray Incorporated (ARAY), Keryx Biopharmaceuticals (KERX)

OraSure Technologies, Inc. (NASDAQ:OSUR) announced its fourth-quarter results after the market closed on Wednesday. The oral fluid diagnostics maker beat analyst expectations by $0.03 per share.

Keep Reading →

February 9th, 2013 - News